D&A at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s D&A?
- Taysha Gene Therapies, Inc. (TSHA) reported D&A of $295K in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s D&A changed year-over-year?
- Taysha Gene Therapies, Inc.'s D&A increased by 4.2% year-over-year, from $283K to $295K.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s D&A?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s D&A has grown at a 19.8% compound annual growth rate (CAGR), from $526K to $1.08M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.